



November 7, 2022

To whom it may concern

Company: Teijin Limited
Representative: Akimoto Uchikawa, President and CEO
Stock code: 3401 (Prime Market, Tokyo Stock Exchange)
Contact: Tomoya Yoshitomi, General Manager
Investor Relations Department
TEL: +81-3-3506-4395

Notice Regarding the Revision of Financial Forecasts and the Dividend Forecast

Teijin Limited (hereinafter, the “Company”) hereby announces that, based on its recent performance, it has revised its consolidated financial forecasts and the dividend forecast for the fiscal year ending March 2023 (April 1, 2022, to March 31, 2023) from the values announced on May 12, 2022. Details are as follows.

1. Revision of consolidated financial forecasts for the fiscal year ended March 31, 2023

	Net sales	Operating income	Ordinary income	Profit attributable to owners of parent	Earnings per share
Previously announced forecast (A)	million yen 1,000,000	million yen 50,000	million yen 52,000	million yen 28,000	Yen 145.74
Revised forecast (B)	1,050,000	25,000	29,000	16,000	83.23
Change (B - A)	50,000	-25,000	-23,000	-12,000	-
Percent change (%)	5.0%	-50.0%	-44.2%	-42.9%	-
(Reference) Results for the previous fiscal year (FY2021)	926,054	44,208	49,692	23,158	120.58

Reasons for the revision of the financial forecasts

We have decided to revise our net sales forecast upward from the previously announced value against the backdrop of the depreciation of the yen and the selling price revisions we have made to pass on the significant increases in raw material and fuel prices. Meanwhile, we have decided to revise our forecasts of operating income, ordinary income and profit attributable to owners of parent downward from the previously announced values. This is because we predict the decrease mainly due to productivity deterioration at US and European bases caused by the labor shortage and a further rise in the natural gas price in Europe in the Materials Business Field, and the replacement of *FEBURIC*, a pharmaceutical product with generic alternatives faster than expected in the Healthcare Business Field.

2. Revision of the dividend forecast

	Dividend per share		
	End of the 2Q	End of the fiscal year	Total
Previously announced forecast	¥27.50	¥27.50	¥55.00
Revised forecast		¥12.50	¥40.00
Actual amount for FY2022	¥27.50		
(Reference) Results for the previous fiscal year (FY2021)	¥27.50	¥27.50	¥55.00

Reasons for the revision of the dividend forecast

Regarding decisions on paying dividends from surplus, the Company has adopted the basic policy of keeping dividends in proportion to its operating results while giving due consideration to the need for stable, sustained dividend payment.

Although we decided to pay an interim dividend of 27.5 yen per share, we have revised our forecast of the year-end dividend to 12.5 yen per share based on the latest revision of our consolidated financial forecasts. Accordingly, the annual dividend for the fiscal year ending March 2023 will be 40 yen per share.

- End -